HOME >> MEDICINE >> NEWS
New agreement questions NHS relation with industry

The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published on bmj.com today.

Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.

But before embracing this agreement with open arms, we should examine what it actually says and what the deeper implications might be, warns Professor Michael Goodyear of Dalhousie University, Canada.

The agreement is the product of a unique consortium of industry, government, and academia, but other organisations, such as the Central Office for Research Ethics Committees, are not mentioned, despite being central to many issues covered in the agreement.

The agreement also applies only to contract research (commercial, industry sponsored trials usually directed towards pharmaceutical product licensing). It does not apply to phase I testing with healthy volunteers (as in TGN1412), to studies initiated by investigators, to trials in which the sponsor merely provides funding, or to research in non-NHS institutions.

While collaboration is admirable, we must realise that the development of a business model for research is a primary motivation behind this initiative, says Goodyear. As the guidance document states, the NHS is being "harnessed" in what is essentially a competitive model.

A surprising and disturbing element of the agreement relates to the crucial principles of transparency and accountability in research. Rather than incorporating and upholding the new and widely supported standards for an open research culture, the agreement has embedded an older and more problematic industry standard.

And, given that this agreement appears at a time when public trust in the drug industry
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
16-Nov-2006


Page: 1 2

Related medicine news :

1. Heading to Siberia: UH signs agreement with Russian Academy of Sciences
2. Research agreement to advance new imaging technology
3. Access to science enhanced by new NIH-ASH agreement
4. Patent laws and US trade agreements are hindering access to HIV treatment
5. Stevens in agreement with Competitive Technologies to commercialize Stevens IP worldwide
6. GE Healthcare and St. Josephs Hospital and Medical Center, Phoenix announce research agreement
7. New licensing agreement to maximize AIDS drug development
8. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
9. Microbicide field praises agreement to license new AIDS drugs
10. Implementing European Space Policy: Key ESA/EC agreement on Earth Observation data signed today
11. Proteome Systems signs agreement with Prince Henrys Institute for Ovarian Cancer Diagnostic Test

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New agreement questions NHS relation with industry

(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... --  Physicians Rx Pharmacy ("PRxP") today announced that ... as President and Chief Executive Officer.  Mr. ... Executive Officer for Soleo Health Specialty Infusion Services, will, ... Pharmacy, be responsible for leading the rapidly-growing 340B pharmacy ... bring Gaston on as the President and CEO of ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has ... (London, UK - November 19-20, 2015)" conference to ... will cover industry case studies, regulatory updates, latest therapies ... Dr Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2
Cached News: